March 11, 2025

Starting a career to drive positive change

Grace Newman, a recent graduate who joined FIECON in September 2024, shares her journey and experiences as an Associate, offering insights for recent graduates interested in joining the team.

What inspired you to join FIECON ?

I studied economics at university, and during my third year, I had the opportunity to complete a placement year within the pharmaceutical industry, which solidified my goal of applying my economics skills to make a meaningful impact on people’s lives. This experience sparked my desire to work in health economics, and joining a consultancy like FIECON felt like the perfect next step. The opportunity to work with a diverse set of clients across various products and disease areas offers a breadth of experience that is particularly valuable for someone starting their career in health economics. The variety of projects ensures constant learning and growth, which is exactly what I was looking for.

Additionally, FIECON’s core mission resonated strongly with me because it focuses on using health economics to improve global wellbeing and bring life-changing drugs to market. This emphasis on public health was a pivotal factor in my decision to pursue a career in health economics. The company’s B Corp certification further demonstrated that it not only cares about making an impact through healthcare but also strives to make a positive difference in the lives of its people, clients, and society at large.

Associate, Grace Newman in the FIECON office

What have you been working on at FIECON since you started in September?

Since joining FIECON, I’ve had the privilege of working on a variety of exciting projects across different disease areas. I’ve contributed to economic modeling, outcomes research, value communications, and NICE HTA submissions, all while being part of supportive and knowledgeable project teams. These experiences have helped me build valuable industry knowledge and refine my client relationship skills.

What I’ve come to realise is that the people at FIECON truly make it a unique and enjoyable place to work. From day one, the wider team made me and the other new associates feel incredibly welcome and integral to the company. I’ve learned so much from my colleagues, and their support has been instrumental in my professional development.

I can genuinely say I’m learning every day at FIECON. The working environment is highly encouraging, which has boosted confidence in my skills. As I continue to work on various projects, I feel increasingly assured in my ability to contribute meaningfully.

What advice would you give to graduates interested in pursuing a career here?

For recent graduates looking to pursue a career at FIECON, my advice would be to familiarise yourself with the company’s values. FIECON is driven by its mission to make a positive impact in healthcare and society, and these values should resonate with you as well. Understanding the company’s ethos will guide your work and career aspirations. FIECON isn’t just about delivering on projects—it’s about contributing to something larger than yourself, and if that aligns with your values, then you’ll thrive here.

Company updates

NICE published surrogate endpoints guidance: insights from Dawn
On January 20th, NICE published a new report offering best practice recommendations for using surrogate endpoints in health economic models. In this interview, Dawn Lee, a member of FIECON's Strategic Council who participated in the meetings to develop the guidance and reviewed the draft, shares her insights as a NICE committee member.
Read more
Stories over statistics: Richard and Caroline talk about Rare Disease
As Rare Disease Day approaches, Caroline, Associate Director at FIECON, and Richard, Head of Client Partnerships at FIECON, discuss the crucial role of HEOR in improving the lives of rare disease patients, and their families and care givers.
Read more
Why Saudi Arabia is the next key market for your Pharma Expansion
In this informative conversation, Lavni Varyani from Pharma BP discusses the evolving HTA process in Saudi Arabia. As a GCC market expert, Lavni explains how pharmaceutical companies can strategically engage with the market to navigate the upcoming HTA changes from both local and global perspectives.
Read more